Versant Capital Management’s ADMA Biologics ADMA Stock Holding History

Versant Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.12K	Hold	112	–	–	﹤0.01%	2694
2026 Q2	$937	Sell	112 -766	-87%	-$6.98K	﹤0.01%	2647
2026 Q1	$7.91K	Sell	878 -971	-53%	-$15.3K	﹤0.01%	2231
2025 Q4	$33.7K	Buy	1,849 +1,277	+223%	+$21.5K	﹤0.01%	1317
2025 Q3	$8.39K	Sell	572 -123	-18%	-$2.11K	﹤0.01%	2014
2025 Q2	$12.7K	Sell	695 -11	-2%	-$224	﹤0.01%	1781
2025 Q1	$14K	Buy	+706	New	+$12.2K	﹤0.01%	1535

Other funds holding ADMA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Versant Capital Management's ADMA Position: Q3 2026 in Review

Versant Capital Management held its ADMA Biologics (ADMA) position steady in Q3 2026 at 112 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2694.

Versant Capital Management first reported a position in ADMA in Q1 2025 and has held it in 7 quarters since. The position peaked at $33.7K in Q4 2025. 179 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

Versant Capital Management held 112 shares of ADMA Biologics worth $1.12K as of Q3 2026.
Versant Capital Management left its ADMA Biologics share count unchanged in Q3 2026.
ADMA Biologics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2694 holding.
Versant Capital Management first reported a position in ADMA Biologics in Q1 2025 and has held it in 7 quarters since.
Versant Capital Management's ADMA Biologics position peaked at $33.7K in Q4 2025.
179 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.